AzTrials
AzTrials

AchalasiavMIINCT00604942

vMII for Measurement of Oesophageal Bolus Transport and Reflux

A study testing Heller's Myotomy, Nissen Fundoplication and domperidone or esomeprazole (Conservative management) in people with Achalasia and GORD, run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Recent work at St. Thomas' has validated an innovative new design of a multichannel intraluminal impedance (MII) catheter that is sensitive to variation in oesophageal volume in healthy volunteers and patients. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Achalasia, GORD
What is being tested?
Heller's Myotomy, Nissen Fundoplication and domperidone or esomeprazole (Conservative management)
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
140 participants
Where
1 siteUnited Kingdom
Study dates
Nov 2007to Oct 2010
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • male or female
  • at least 18 years of age
  • have given informed consent for the vMII and Barium videofluoroscopy
  • have symptoms of reflux, dysphagia, have known achalasia or are planned for anti-reflux surgery

Who cannot join

  • with medications influencing gastrointestinal function within 3 days of the study
  • with those on anticoagulants
  • with any hematological abnormalities
  • with any evidence of infectious disease
  • who are pregnant or breast-feeding or sexually active and not on contraception.
  • with evidence or history of drug or alcohol abuse within the past two years
Show all 10Show fewer
  • with diabetes mellitus
  • with severe physical or mental health concerns on screening which may contribute to the ability to comply with study requirements
  • with active co-morbid conditions
  • with oesophageal surgery or stent (dilation acceptable)

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Oesophageal Laboratory, GSTT

    London, London, SE1 7EH

Other trials in United Kingdom

About this study

Official title: Volume Sensitive Multichannel Intraluminal Impedance (vMII) for the Measurement of Oesophageal Bolus Transport and Reflux

Recent work at St. Thomas' has validated an innovative new design of a multichannel intraluminal impedance (MII) catheter that is sensitive to variation in oesophageal volume in healthy volunteers and patients. This project will establish the clinical value of volume sensitive MII (vMII) compared to conventional MII acquired simultaneously by the same catheter (ROC analysis). Studies will assess:

  1. The accuracy of volume measurements and correlation between symptoms and the volume of bolus retention in patients with dysphagia.
  2. The accuracy of volume measurements and correlation between symptoms and reflux volume in patients with reflux disease.
Read more

Follow up studies after appropriate treatment will assess whether symptomatic improvement is associated with a reduction in oesophageal volume retention/reflux.

The vMII technique will be applied with high resolution manometry (HRM). These investigations are complementary in that vMII assesses the success or failure of bolus transport (or occurrence of reflux) and HRM can assess:

  1. the oesophageal dysfunction that results in bolus escape
  2. the abnormal events at the gastro-oesophageal junction (reflux barrier) that allow reflux to occur. with a reduction in oesophageal volume retention / reflux.
Read the detailed description

Swallowing problems and gastro-oesophageal reflux disease (GORD) are common in the community with important effects on health, quality of life and NHS costs. Furthermore, these problems may explain the increasing rate of oesophageal cancer. These concerns highlight the importance of appropriate investigation and management of these symptoms.

Medications that suppress gastric acid relieve symptoms in many patients; however this does not improve oesophageal function or reduce 'non-acid' reflux from the stomach. At least 1 in 4 patients have symptoms despite treatment and further management of these individuals is challenging. Conventional multichannel intraluminal impedance (MII) studies assess swallowing function and reflux, but cannot assess volume. This is important because larger volumes of food stuck in the oesophagus and failure to clear larger amounts of irritant reflux from the stomach are more likely to cause symptoms and damage to the lining of the oesophagus.

The proposed project builds on recent work at St. Thomas' in which a new MII technique was shown to detect changes in oesophageal volume. The aim is to assess whether this volume sensitive MII (vMII) is useful in clinical practice.

Patients with swallowing problems and reflux symptoms will undergo vMII and High Resolution Manometry in unison in a combined Catheter Assembly during a test meal containing barium (known as videofluoroscopy) as it is visible on x-ray. The volume of fluid stuck in the oesophagus or refluxing from the stomach will be measured by both vMII and videofluoroscopy and the problems with motility will be assessed with HRM. The results will be compared and the link between oesophageal volume, dysmotility and symptoms will be examined. Finally the studies will be repeated after treatment (videofluoroscopy being offered only males and women over 40) to see if improvements are linked to reduced volume measurements.

In routine clinical practice, successful vMII would reduce the need for barium swallows (therefore reducing exposure to radiation) and improve the ability to link oesophageal dysfunction and reflux events with symptoms, and thus guide further management in patients that fail to respond to standard treatments.

Existing measurements of oesophageal function assess the presence or absence of acid (pH), bolus transport (HRM) or fluid (conventional MII) in the oesophagus, but are not sensitive to volume change. It is thought that this explains the failure to establish the cause of oesophageal symptoms in some patients (Sifrim Gut 06). Firstly because retention and reflux of large volumes in the oesophagus is more likely to cause symptoms. Secondly because conventional MII lacks sensitivity in patients with poor emptying of residual fluid in the oesophagus much of the time (e.g. achalasia, post-fundoplication). Volume sensitive MII (vMII) is a novel adaptation of catheter technology that is sensitive to volume changes in the oesophagus of healthy volunteers (Fox DDW 06). It is a non disposable catheter which is 3mm in diameter and is very similar to the impedance and pH manometry catheters routinely used at St Thomas' and many other hospitals and are well tolerated by patients.

Study Design and Methodology Studies will be performed in two, well-defined patient populations that represent the two cardinal presenting symptoms in oesophageal disease.

  1. Patients with swallowing difficulty (dysphagia) related to achalasia
  2. Patients with reflux symptoms referred for consideration of fundoplication. Individuals (age 18-65 years) referred to the oesophageal laboratory for investigation will be invited to participate. All participants will undergo complete physical and mental health questionnaires, and an assessment of predominant complaint and symptom severity.

This study will test two key issues in order to compare the clinical value of volume measurements by vMII to existing techniques in these two patient populations.

  1. Stationary: The accuracy of volume measurements acquired by vMII in patients with oesophageal disease compared to videofluoroscopy (gold standard).
  2. Ambulatory: The association of volume measurements with symptoms compared to conventional pH / MII measurements before and after treatment.
Conditions
Achalasia, GORD
Being tested
Heller's Myotomy, Nissen Fundoplication, domperidone or esomeprazole (Conservative management), Esomeprazole 40 mg
Keywords
Oesophagus, Dysphagia, Impedance, High Resolution Manometry, Peristalsis, Contractile Pressure, Coordination of contraction, Bolus transport
Medical subject headings
Esophageal Achalasia, Deglutition Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Heller's MyotomyProcedure or surgery

    Long vs Short Heller's Myotomy for Achalasia

  • Nissen FundoplicationProcedure or surgery

    Partial vs Full Fundoplication for GORD

  • domperidone or esomeprazole (Conservative management)Drug

    Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg

  • Esomeprazole 40 mgDrug

    Esomeprazole vs no esomeprazole for GORD not referred for surgery

Study groups in NCT00604942
Study groupRoleWhat they receive
AchalasiaExperimentalLong vs Short Myotomy repair of Achalasia
Receives: Procedure: Heller's Myotomy
Dysphagia controlExperimentalConservative Management
Receives: Drug: domperidone or esomeprazole (Conservative management)
GORD for surgeryExperimentalPartial vs Full Fundoplication repair
Receives: Procedure: Nissen Fundoplication
GORD not for surgeryExperimentalesomeprazole 40 mg vs no esomeprazole
Receives: Drug: Esomeprazole 40 mg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Does vMII provide an accurate assessment of volume in disease?

    Measured: 3 years

  2. Does vMII assessment of volume improve the accuracy with which 'events' are associated with symp?

    Measured: 3 years

  3. Does symp improvement post treatment correlate with reduced 'volume events'?.

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jan 2008 (estimated)
  2. Study startNov 2007
  3. Primary completionOct 2010 (estimated)
  4. Study completionOct 2010 (estimated)

Why it stopped: prototype catheter never delivered

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00604942
Sponsor's protocol ID
07/H0802/73
Acronym
vMII
Status last verified
Jul 2009
First submitted
15 Jan 2008
Last updated
3 Aug 2009
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Heller's Myotomy, Nissen Fundoplication and domperidone or esomeprazole (Conservative management) in people with Achalasia and GORD, run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 3 Aug 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: prototype catheter never delivered). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Does vMII provide an accurate assessment of volume in disease? (time frame: 3 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in